Suit

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Suit

Property Description
Active Ingredient Piroxicam
Form Capsules, tablets, injection solution, topical gel
Pharmacological Class Nonsteroidal Anti-Inflammatory Drug (NSAID)
Common Action Anti-inflammatory, analgesic, antipyretic
Origin Synthetic, oxicam derivative

What Type of Medicine is Suit?

Suit is a pharmaceutical preparation containing the active substance Piroxicam, which is classified as a Nonsteroidal Anti-Inflammatory Drug (NSAID). This places it in a category of medicines used globally to manage symptoms related to pain, inflammation, and stiffness. Chemically, Piroxicam is a synthetic compound and belongs to the oxicam derivative subclass of NSAIDs, distinguishing it from many other common pain relievers. Piroxicam’s structure and properties are well-documented. This classification indicates that the medication works by addressing the inflammatory response within the body.


Composition, Forms, and General Purpose

As a single-ingredient product, Suit's therapeutic action relies solely on Piroxicam. The medication is manufactured in several high-level dosage forms, including oral solid forms, solutions for intramuscular (IM) injection, and topical gels, allowing for various routes of administration. The general purpose of Suit is to provide comprehensive symptomatic relief through its primary actions: an anti-inflammatory effect to reduce swelling, an analgesic effect for pain relief, and an antipyretic effect to help lower fever. Piroxicam is clinically recognized for its use in managing chronic joint stiffness and pain. The effectiveness of Piroxicam for controlling pain in chronic conditions has been established. The ultimate aim of the medication is to manage the discomfort and stiffness tied to underlying inflammatory processes.

What side effects are possible with Suit?

Possible side effects and safety information

The safety profile of Suit (Piroxicam), a Nonsteroidal Anti-Inflammatory Drug (NSAID), is categorized based on its potential effects on major physiological systems, as documented in official regulatory sources like the EMA and FDA.


Key Adverse Reaction Categories

Adverse reactions are officially classified by frequency. Common reactions often involve the Gastrointestinal Disorders (e.g., nausea, abdominal pain, dyspepsia) and Nervous System Disorders (e.g., headache, dizziness). Fluid retention, documented as edema, is also listed as a common general disorder.

System-Organ Class (SOC) Examples of Officially Listed Reactions
Gastrointestinal Disorders Ulceration, bleeding, perforation
Cardiovascular/Vascular Disorders Myocardial infarction, stroke, hypertension
Skin and Subcutaneous Disorders Severe Cutaneous Adverse Reactions (SCARs)
Renal and Urinary Disorders Renal toxicity, papillary necrosis

Serious Adverse Reactions and Safety Patterns

The most serious documented risks are potentially fatal cardiovascular thrombotic events (myocardial infarction and stroke) and gastrointestinal complications (bleeding, ulceration, and perforation), which can occur at any time during use. Severe skin reactions, such as Stevens-Johnson Syndrome (SJS), are explicitly documented, often appearing more significantly at the start of treatment.

Official labels note that the risk of serious cardiovascular events may increase with duration of use.


Population-Specific Safety Constraints

Regulatory documents include specific safety constraints for certain groups. Older adults are documented as being at a greater risk for serious gastrointestinal events. Use is generally restricted or contraindicated in patients with a history of post-Coronary Artery Bypass Graft (CABG) surgery pain and is advised to be avoided in women after 30 weeks of pregnancy due to fetal risk. Caution is required for patients with advanced renal disease.

Overdose and Emergency Response

Overdose and when to seek help

A suspected overdose of Suit (Piroxicam) requires immediate contact with emergency medical services or a poison control center, as stated in regulatory guidelines. Delay in seeking professional help should be avoided. Overdose manifestations are primarily documented across the gastrointestinal and nervous systems. Initial signs may include severe headache, confusion, nausea, vomiting, or stomach pain, alongside symptoms like ringing in the ears (tinnitus).

Regulators document that overdose carries a serious risk of progressing to life-threatening outcomes. These severe manifestations include convulsions (seizures), lack of responsiveness leading to coma, severe gastrointestinal bleeding, and low blood pressure potentially resulting in shock. Due to these potential complications, continuous hospital observation and monitoring of vital signs are required.

Official regulatory information confirms that no specific antidote is known for Piroxicam toxicity. Treatment focuses entirely on symptomatic and supportive measures, such as administration of activated charcoal to reduce drug absorption and the use of intravenous fluids to maintain stability. A higher risk of serious complications, particularly severe gastrointestinal issues, is noted in elderly patients and those with pre-existing kidney or liver disease.

Therapeutic Uses of Suit

What Suit Treats: Main Uses and Benefits

Suit is considered relevant for symptomatic relief across key therapeutic domains, applied in situations where additional management of discomfort is required to ease the overall symptom burden. It is used in situations involving certain distressing symptoms to contribute to improved comfort during periods of heightened symptoms. The medication may be part of symptomatic management in situations where patients experience discomfort linked to inflammatory or irritative processes.

It is commonly used across conditions presenting with episodic or fluctuating symptom patterns, including rheumatoid arthritis, osteoarthritis, acute gouty arthritis, specific musculoskeletal injuries (like sprains or tendinitis), and primary dysmenorrhea. It is helpful in situations where multiple symptoms occur together, applied in addressing symptoms related to physical discomfort, stiffness, and noticeable swelling.

“Suit helps manage symptom clusters that may become intense or disruptive, assisting with maintaining functional stability during periods of heightened discomfort.”

It is relevant in contexts involving heightened systemic burden, applied during phases when symptoms become more noticeable, such as during episodes of sudden symptom escalation. This support provides supportive relief when symptoms interfere with routine activities.

Quick Fact: Relief for Pain and Inflammation
Suit is applied across domains where additional symptomatic support is needed to address chronic pain, morning stiffness, and acute swelling.

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Suit (Piroxicam) — Official Regulatory Information

Suit, which contains the Nonsteroidal Anti-Inflammatory Drug (NSAID) Piroxicam, has strict eligibility rules established by government regulatory bodies.

Category Official Regulatory Status
Populations for whom use is allowed (as stated in label): Adults with chronic inflammatory conditions (e.g., osteoarthritis, rheumatoid arthritis).
Populations for whom use is contraindicated: Known hypersensitivity to Piroxicam or any other NSAID, including aspirin. Patients in the peri-operative setting of CABG surgery. Individuals with active GI ulceration, bleeding, or perforation.
Age-related eligibility rules: Pediatric Population: Safety and efficacy have not been established. Older Adults (65+): Use requires caution due to increased risk of serious GI and renal events.
Condition-specific eligibility rules: Contraindicated in severe heart failure, advanced renal disease, and severe hepatic impairment.
Pregnancy and lactation eligibility status: Avoid use from 30 weeks gestation onward. Not recommended for use by breastfeeding women.

Eligibility classifications (high-level): The drug is generally Contraindicated for those with severe organ impairment or active GI disease. It is Use with Caution for the elderly and those with pre-existing, non-severe organ dysfunction, and Not Established for use in children under 18. These regulatory classifications define strict limits for eligibility.

What should I know about interactions with other medicines?

Suit Interactions with other medicines and products

This section outlines the documented interaction patterns of Suit (Piroxicam) as officially recognized in government regulatory information, which often define specific restrictions for co-administration.

Formally Contraindicated Combinations

Certain combinations are expressly prohibited by regulatory authorities due to high interaction risk:

  • Other Nonsteroidal Anti-Inflammatory Drugs (NSAIDs): Use with other NSAIDs, including COX-2 selective inhibitors, is contraindicated due to a significantly increased risk of serious gastrointestinal adverse events.
  • Peri-operative Pain: The use of Suit for the treatment of pain in the setting of Coronary Artery Bypass Graft (CABG) surgery is contraindicated.

Pharmacodynamic and Bleeding Risks

Co-administration with medicines that affect blood clotting or hemostasis increases the potential for serious bleeding or hemorrhage. This category includes:

  • Anticoagulants (e.g., Warfarin)
  • Antiplatelet Agents (e.g., analgesic doses of Aspirin)
  • Selective Serotonin Reuptake Inhibitors (SSRIs) and SNRIs

Pharmacokinetic and Exposure Alterations

These interactions may affect the concentration of Suit or the co-administered drug in the body:

  • Lithium and Methotrexate: Suit can elevate the steady-state plasma concentrations of Lithium and Methotrexate, raising the risk of toxicity from those medicines.
  • CYP2C9 Metabolism: Piroxicam is cleared primarily via the CYP2C9 enzyme. Individuals who are genetically classified as CYP2C9 poor metabolizers have reduced clearance, resulting in abnormally high plasma levels of Suit.

Fluid Balance and Blood Pressure

  • Antihypertensives (ACE Inhibitors, ARBs, Beta-Blockers): Suit may diminish the blood pressure-lowering effect of these medicines.
  • Diuretics: NSAIDs can reduce the salt- and water-excreting (natriuretic) effect of diuretics (e.g., Furosemide, Thiazides).

Population-Specific Notes

When Suit is co-administered with ACE Inhibitors or ARBs, an increased risk of renal function deterioration is noted in the labels for the elderly, volume depleted, or patients with renal impairment.

Mechanism of Action

The Inhibition of Phosphodiesterase Type 5 (PDE5)

Suit is a selective inhibitor that acts on the Phosphodiesterase type 5 (PDE5) enzyme, which is expressed in the smooth muscle cells of specific vascular tissues. By competitively binding to PDE5, Suit restricts the enzymatic breakdown of the key second messenger molecule, cyclic Guanosine Monophosphate (cGMP). This action restricts the degradation of cGMP, defining the primary molecular effect of the drug.


Modulation of Vascular Smooth Muscle Tone

The subsequent accumulation of cGMP within the cell activates a cascade that causes the smooth muscle lining the blood vessel walls to relax (vasodilation). This action occurs within the domain of peripheral vascular regulation. The resulting physiological effect is the increase of localized blood flow and a reduction in vascular resistance in the targeted areas.


Dependence on Nitric Oxide Signaling

Suit's mechanism is contingent on the body's natural release of Nitric Oxide (NO) to produce cGMP. It functions by inhibiting the enzymatic process that would otherwise terminate the cGMP-mediated cellular signal.

Dosage and Administration Information

Administration and Dosage

Suit is a prescription medication and must be taken exactly as directed by a healthcare professional. Dosage and administration frequency are individualized based on the specific condition being treated, the patient’s response, and other concurrent medications. Do not adjust the dose or stop taking the medication without consulting your doctor.

General Usage Guidelines

  • Oral Administration: If taking the tablet form, swallow it whole with a full glass of water. Do not crush, chew, or break the tablet unless specifically instructed by your pharmacist or doctor. Breaking the tablet may affect how the medicine is absorbed.
  • Timing: The drug is often prescribed to be taken at evenly spaced intervals throughout the day and night to maintain a consistent level in the bloodstream. If a dose is missed, take it as soon as you remember, unless it is almost time for the next scheduled dose. In that case, skip the missed dose and resume your regular schedule. Do not take a double dose to compensate for the missed one.
  • Food: Follow your doctor’s or pharmacist’s instructions regarding taking Suit with or without food, as this can vary depending on the exact formulation and its intended effect. Taking some forms with food can help prevent stomach upset.
  • Duration of Therapy: Complete the full course of treatment as prescribed, even if symptoms improve early. Discontinuation of the medication prematurely may lead to a relapse of the underlying condition. Always attend follow-up appointments and laboratory tests as recommended by your physician to monitor your progress and check for potential side effects.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Phase 3 Clinical Trial Findings

Research evidence has explored the duration and extent of symptom change in patients with moderate to severe plaque psoriasis who received the combination. Studies followed participants for up to 52 weeks.

Areas of investigation explored:

  • Reduction in Disease Severity: The primary endpoint, defined as a 75% improvement in the Psoriasis Area and Severity Index (PASI 75), was observed in a higher percentage of participants receiving the combined regimen compared to those receiving placebo or monotherapy.
  • Skin Clearance: The percentage of participants achieving clear or almost clear skin (Physician’s Global Assessment [PGA] 0/1) was measured at week 16.
  • Symptom Changes: Studies investigated whether there was a change in symptoms like itching and redness across the study period.

Safety Profile and Long-Term Use

Research has explored the degree of response in participants during the study.

Long-term studies examined the safety profile of the combined regimen during chronic use and investigated whether there was a change in the frequency of flare-ups.

Safety data evaluated in trials:

  • Adverse Events (AEs): The overall incidence and type of adverse events were tracked across treatment groups.
  • Liver Impairment: Studies have evaluated the use of this drug combination in people with severe liver impairment.
  • Infections: Rates of serious infections were monitored in all study groups over the course of the trials.

Comparative Efficacy Research

Comparative trials explored the differences in measured outcomes between this treatment and other treatments. These studies evaluated measured responses in key metrics such as PASI 75 and PGA scores.

Patient-Reported Outcomes (PROs)

Studies evaluated quality of life metrics and differences were observed when compared to placebo. Research examined the time to observed changes in symptoms, with initial changes noted within the first four weeks of therapy in some study participants.

Frequently Asked Questions (FAQ)

Common questions about Suit (FAQ)


Q: How quickly does Suit typically start to show its effects?

According to official product information, peak concentrations of the drug in the blood plasma are generally reached within three to five hours after taking the oral dose. While the drug starts acting quickly at a molecular level, the full therapeutic effects related to changes in symptoms may take several weeks to progressively increase during the course of therapy.


Q: How long does Suit stay in the body after the last dose is taken?

Regulatory information indicates that the drug has a prolonged elimination half-life, which is approximately 50 hours in adults. This means it takes an extended period of time for the body to substantially clear the medicine from the plasma once its use has stopped.


Q: What is the general expectation for the length of time Suit's effects last?

The prolonged half-life of about 50 hours is the reason the medication is designed for single-daily use. This pharmacokinetic property allows the drug to maintain relatively stable concentrations in the bloodstream, which supports a sustained duration of effect throughout the day.


Q: Why is the official dosage described in a range rather than a single number?

Official guidance states that dosage is individualized to meet specific patient treatment goals and depends on a person's response to the initial therapy. Regulatory documents emphasize using the lowest effective dosage for the shortest duration necessary to control symptoms.


Q: Are there specific times of day that Suit is described as being best to take?

Regulatory labeling often describes use as a single dose taken once daily. Official documents recommend that oral forms of the medication be taken preferably with or immediately after food.


Q: Can Suit be used by individuals who are lactose intolerant?

Some oral forms of the medication contain lactose monohydrate as an inactive ingredient, which is listed in the official Summary of Product Characteristics (SmPC). Patients with a known intolerance to lactose are often advised to review the excipient list with a healthcare provider for their specific formulation.


Q: What is the process described for stopping the use of Suit?

Regulatory guidance specifies that the drug should be discontinued immediately if a serious adverse event, such as a severe skin reaction or a major gastrointestinal complication, is suspected or occurs during treatment. For reasons other than emergency safety events, stopping the medication is typically done in consultation with a prescribing healthcare professional.


Q: Can Suit be crushed or split if a patient has trouble swallowing official doses?

The instruction not to crush, chew, or break the tablet is based on the fact that altering the form of the tablet may affect how the medicine is absorbed by the body. This is a general rule stated in official documents for oral formulations.


Q: What are the most frequent reasons patients discontinue Suit in clinical studies?

Analysis of clinical trial data indicates that patients discontinue therapy frequently due to both a lack of efficacy (the drug not working as expected) and the occurrence of adverse events that become unmanageable or intolerable.


Q: How is Suit different from other common medications used for similar conditions?

Suit, which contains Piroxicam, is chemically classified as an oxicam derivative. This is a factual chemical distinction that separates it from other Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) that belong to other chemical classes, such as propionic acids (like ibuprofen) or acetic acids (like diclofenac).


Q: Does Suit have the same active ingredient as any older, known medicines?

The active ingredient in Suit is Piroxicam. Piroxicam is the generic name for the substance, and it has been the active ingredient in various brand-name products available for many years.


Q: Are there official warnings about taking Suit with over-the-counter pain relievers?

Yes, official warnings advise against taking Suit with other Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), which includes many over-the-counter pain relievers such as aspirin, ibuprofen, and naproxen. This is due to a significantly increased risk of serious gastrointestinal complications.


Q: Does taking Suit affect a patient's ability to drive or operate machinery?

Regulatory information notes that the medication may cause side effects such as drowsiness or dizziness. Official guidance indicates that users should be aware of how the medication affects them before engaging in activities that require full mental alertness, such as driving or operating heavy machinery.


Q: Is it normal to feel a change in appetite after starting Suit?

Patient information from regulatory-supported sources lists loss of appetite as one of the possible side effects that a person may experience while taking the medication.


Q: What is the difference between a common side effect and a rare adverse event for Suit?

Official drug documents classify effects based on how often they occur and their severity. Common effects are those most frequently reported in clinical studies, while a rare or serious adverse event occurs infrequently but is monitored by regulatory bodies for its potential for severe consequences.


Q: Is Suit considered a first-line treatment according to official guidelines?

Official regulatory guidance specifies that, due to its safety profile, this medication should not be used as a first-line treatment when a Nonsteroidal Anti-Inflammatory Drug (NSAID) is indicated.


Q: What is the typical timeframe for a patient to feel Suit's maximum effects?

Maximum stable concentrations of the drug in the plasma (known as steady state), which support the maximum effects, are typically reached in most patients within 7 to 12 days of continuous daily use.

How should Suit be stored and disposed of?

How to Store and Dispose of Suit: Official Requirements

Suit must be stored at controlled room temperature, typically 20^circC to 25^circC (68^circF to 77^circF), and kept away from light and moisture. It is mandatory to keep the medicine in its original container and ensure the container is tightly closed. Do not store the product above 30^circC and do not freeze it.

If the medicine is reconstituted or opened, specific in-use stability rules apply; for example, some forms must be discarded after 28 days even when refrigerated. Always keep Suit out of the reach and sight of children.

To dispose of unused or expired medicine, follow official guidelines. Do not flush the product down the toilet or throw it in household trash. Use an authorized drug take-back program or pharmacy collector to comply with local regulations for pharmaceutical waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Suit found in:

A-Z Index: